Table 2 Characteristics of patients in the primary and held-out cohorts

Number

192

716

43

165

ADC value (10⁻³ mm²/s)

1.15 (0.92, 1.54)

1.54 (1.22, 2.05)

0.001

1.14 (1.08, 1.30)

1.38 (1.14, 1.75)

0.321

LN volume (cm³)

1.31 (0.75, 3.32)

0.41 (0.24, 0.75)

0.001

1.85 (0.90, 4.23)

0.44 (0.27, 0.80)

0.001

Short diameter (mm)

10.93 (8.99, 16.69)

7 (5.94, 8.57)

0.001

14.02 (9.13, 18.19)

7.79 (6.33, 9.12)

0.001

Long diameter (mm)

23.66 (13.06, 35.92)

10.07 (9. 21.64)

0.001

23.97 (20.41, 37.67)

14.42 (9.00, 21.51)

0.001

Short-to-long diameter ratio

0.54 (0.42, 0.67)

0.57 (0.40, 0.68)

0.632

0.56 (0.45, 0.65)

0.57 (0.40, 0.78)

0.660

Patients characteristics

Age (median, IQR, y)

68 (62,74)

70 (65,72)

T-PSA (median, IQR, ng/ml)

47.16 (15.67,89.18)

35.62 (9.25, 48.64)

F-PSA (median, IQR, ng/ml)

5.17 (1.71, 11.22)

4.55 (2.08, 7.05)

F/T PSA (median, IQR, ng/ml)

0.11 (0.07, 0.18)

0.12 (0.09, 0.18)

Gleason score [N (%)]

3 + 4

6 (8.96%)

1 (5.88%)

4 + 3

14 (20.89%)

2 (11.76%)

4 + 4

14 (20.89%)

2 (11.76%)

4 + 5

24 (35.82%)

7 (41.18%)

5 + 4

6 (8.96%)

3 (17.64%)

5 + 5

3 (4.48%)

2 (11.76%)

Pathological T staging [N (%)]

pT2

20 (29.85%)

2 (11.76%)

pT3a

11 (16.42%)

2 (11.76%)

pT3b

22 (32.84%)

12 (70.59%)

pT4

14 (20.89%)

1 (5.88%)

Clinical T staging [N (%)]

T2a

10 (14.93%)

–

T2b

4 (5.97%)

–

T2c

14 (20.89%)

3 (17.65%)

T3a

7 (10.45%)

2(11.76%)

T3b

15 (22.39%)

9 (52.94%)

T4

17 (25.37%)

3 (4.48%)